natgillin/translations-raw huggingface dataset:
Gardasil 9 induced robust anti-HPV 6, anti-HPV 11, anti-HPV 16, anti-HPV 18, anti-HPV 31, anti-HPV 33, anti-HPV 45, anti-HPV 52, and anti-HPV 58 responses measured at Month 7, in 
Merjenje v 7. mesecu, v Protokolih 001, 002, 004, 005, 007 in GDS01C/Protokolu 009, je pokazalo, da je cepivo Gardasil 9 sprožilo močan anti-HPV 6, anti-HPV 11, anti-HPV 16, anti-HPV 18, antiHPV 31, anti-HPV 33, anti-HPV 45, anti-HPV 52 in anti-HPV 58 odziv.
Pyrexia, fatigue, At the injection site: pruritus, bruising 
Pogosti zvišana telesna temperatura, utrujenost; na mestu injiciranja: srbenje, hematom
How to store Gardasil 9 
Kako uporabljati cepivo Gardasil 9
HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3, AIS, Cervical Cancer, VIN 2/3, VaIN 2/3, Vulvar Cancer, and Vaginal Cancer 
CIN 2/3, AIS, rak materničnega vratu, VIN 2/3, VaIN 2/3, rak vulve in rak nožnice, povezani s HPV 31, 33, 45, 52 in
The efficacy of Gardasil 9 against CIN 3 related to vaccine HPV types compared to qHPV vaccine was 100% (95% CI 46.3, 100.0) with 0/5,952 versus 8/5,947 cases. 
Učinkovitost cepiva Gardasil 9 proti CIN 3, povezanim s tipi HPV v cepivu, je bila v primerjavi s qHPV cepivom 100 % (95 % IZ: 46,3; 100,0) s številom primerov 0/5.952 v primerjavi z
The qHPV vaccine was used as an active control during the clinical development program for Gardasil 9. 
V programu kliničnega razvoja cepiva Gardasil 9 so kot primerjalno učinkovino uporabljali qHPV cepivo.
N=Number of individuals randomised to the respective vaccination group who received at least one injection. 
GMT = geometrična sredina titrov cLIA = kompetitivni imunski preizkus Luminex (Competitive Luminex Immunoassay) N = število oseb, randomiziranih v skupino s posameznim cepivom, ki so prejele vsaj eno injekcijo n = število oseb, vključenih v analizo
Prior to agitation, Gardasil 9 may appear as a clear liquid with a white precipitate. 
• Pred pretresanjem ima lahko cepivo Gardasil 9 videz bistre tekočine z belo oborino.
For subjects receiving Gardasil 9 after receiving 3 doses of qHPV vaccine, there was an interval of at least 12 months between completion of vaccination with qHPV vaccine and the start of vaccination with Gardasil 9 with a 3-dose regimen (the time interval ranged from approximately 12 to 36 months). 
Pri preiskovankah, ki so cepivo Gardasil 9 prejele potem, ko so že prejele 3 odmerke qHPV cepiva, je bil razmik med zadnjim cepljenjem s qHPV
Not known (cannot be estimated from the available data) 
Pogostnosti so navedene kot: zelo pogosti (≥ 1/10) pogosti (≥ 1/100 do < 1/10) neznana (ni mogoče oceniti iz razpoložljivih podatkov)
The following side effects can be seen after the use of Gardasil 9: 
Po uporabi cepiva Gardasil 9 se lahko pojavijo naslednji neželeni učinki:
Pre-filled syringe, pack of 10 
PODATKI NA ZUNANJI OVOJNINI BESEDILO NA ŠKATLI napolnjena injekcijska brizga, pakiranje po 10
Injection-site cellulitis 
Infekcijske in parazitske bolezni Neznana celulitis na mestu injiciranja
A total of 92 women were breast-feeding during the vaccination period of the clinical studies of Gardasil 9 in women aged 16 to 26 years. 
V kliničnih študijah s cepivom Gardasil 9 pri ženskah, starih 16 do 26 let, je v obdobju cepljenja dojilo skupno 92 žensk.
1 Type 58 L1 protein 
L1 protein humanega papilomavirusa 1 tipa 58
Vaccination should be postponed in individuals suffering from an acute severe febrile illness. 
Pri osebah, ki imajo akutno hudo bolezen z zvišano telesno temperaturo, je treba cepljenje odložiti.
1 Type 31 L1 protein 
L1 protein humanega papilomavirusa 1 tipa 31
1 Type 33 L1 protein 
L1 protein humanega papilomavirusa 1 tipa 33
HPV 31-, 33-, 45-, 52-, 58-related VIN 2/3, VaIN 2/3 
VIN 2/3 in VaIN 2/3, povezani s HPV 31, 33, 45, 52 in 58
1 Type 45 L1 protein 
L1 protein humanega papilomavirusa 1 tipa 45
1 Type 52 L1 protein 
L1 protein humanega papilomavirusa 1 tipa 52
1 Type 6 L1 protein 
L1 protein humanega papilomavirusa 1 tipa 6
Clear liquid with white precipitate. 
suspenzija za injiciranje bistra tekočina z belo usedlino
HPV 31-, 33-, 45-, 52-, 58-related CIN2 
CIN2, povezane s HPV 31, 33, 45, 52 in
HPV 31-, 33-, 45-, 52-, 58-related CIN3 
CIN3, povezane s HPV 31, 33, 45, 52 in
HPV types. 
1 tipa 45
• Gardasil 9 may appear as a clear liquid with a white precipitate prior to agitation. 
• Preden ga pretresemo, je cepivo Gardasil 9 bistra tekočina z belo oborino.
The PPE population consisted of individuals who received all 3 vaccinations with qHPV vaccine in the base study within 1 year of enrolment without major deviations from the study protocol, were seronegative to the relevant HPV type(s) (types 6, 11, 16, and 18) prior to dose 1, and among subjects 16 years and older at enrolment in the base study, PCR negative to the relevant HPV type(s) prior to dose 1 through one month postdose 3 (Month 7). 
Osebe so bile seronegativne za zadevni tip (zadevne tipe) HPV (tipi 6, 11, 16 in 18) pred 1. odmerkom ter med osebami starimi 16 let ali več ob vključitvi v izhodiščno študijo, PCR negativne za zadevni tip (zadevne tipe) HPV pred 1. odmerkom in tekom enega meseca po 3. odmerku (7. mesec).
Intramuscular use. 
Navodilo za uporabo
HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3 or AIS 
CIN 2/3 ali AIS, povezane s HPV 31, 33, 45, 52 in 58
- If you or your child get any side effects, talk to your doctor, pharmacist or nurse. 
- Če pri sebi oz. otroku opazite kateri koli neželeni učinek, se posvetujte z zdravnikom,
First injection: at chosen date 
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
If you forget one dose of Gardasil 9 
Če enega odmerka cepiva Gardasil 9 niste prejeli
The usual dose is one 1,340-microgram capsule once a day for three weeks, followed by a week when the patient does not take any capsules. 
Običajni odmerek je ena 1 340mikrogramska kapsula enkrat dnevno v obdobju treh tednov, ki mu sledi obdobje enega tedna, v katerem bolnik ne jemlje kapsul.
The full EPAR for Fotivda can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Fotivda je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The most common side effects are high blood pressure (which occurs in almost half of patients) and voice changes, tiredness and diarrhoea (which occur in about a quarter of patients). 
Najpogostejši neželeni učinki so visok krvni tlak (ki se pojavi pri skoraj polovici bolnikov) in spremembe glasu, utrujenost in driska (ki se pojavijo pri približno četrtini bolnikov).
What measures are being taken to ensure the safe and effective use of Fotivda? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Fotivda?
It is not intended to provide practical advice on how to use Fotivda. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Fotivda is available as capsules (890 and 1,340 micrograms). 
Zdravilo Fotivda je na voljo v obliki kapsul (890 μg in 1 340 μg).
What is Fotivda and what is it used for? 
Kaj je zdravilo Fotivda in za kaj se uporablja?
A main study of 517 patients with advanced renal cell carcinoma that had either come back or spread to other parts of the body has shown that Fotivda can help stop the disease from getting worse. 
Glavna študija s 517 bolniki z napredovalim karcinomom ledvičnih celic, ki se je ponovil ali razširil v druge dele telesa, je dokazala, da lahko zdravilo Fotivda zaustavi poslabšanje bolezni.
If the patient has troublesome side effects, the doctor may decide to switch to the lower-strength 890-microgram capsules or interrupt treatment. 
Če se pri bolniku pojavijo problematični neželeni učinki, se lahko zdravnik odloči za prehod na 890-mikrogramske kapsule nižje jakosti ali prekinitev zdravljenja.
This is a summary of the European public assessment report (EPAR) for Fotivda. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Fotivda.
Other information about Fotivda 
Druge informacije o zdravilu Fotivda
The most common side effects with Fotivda are considered manageable, although they may affect the patient's quality of life. 
Najpogostejši neželeni učinki zdravila Fotivda veljajo za obvladljive, čeprav lahko vplivajo na kakovost bolnikovega življenja.
The patients should continue repeating this 4-week course for as long as the disease does not get worse or until side effects become unacceptable. 
Bolniki morajo ta štiritedenski cikel zdravljenja ponavljati, dokler se bolezen ne poslabša ali dokler neželeni učinki ne postanejo nesprejemljivi.
What benefits of Fotivda have been shown in studies? 
Kakšne koristi je zdravilo Fotivda izkazalo v študijah?
Why is Fotivda approved? 
Zakaj je bilo zdravilo Fotivda odobreno?
The most important serious side effect with Fotivda is high blood pressure. 
Najpomembnejši neželeni učinek zdravila Fotivda je visok krvni tlak.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fotivda have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Fotivda upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
What are the risks associated with Fotivda? 
Kakšna tveganja so povezana z zdravilom Fotivda?
In this study, patients taking Fotivda lived for longer without their disease worsening (12 months) than those given another approved medicine sorafenib (9 months). 
V tej študiji so bolniki, ki so jemali zdravilo Fotivda, brez poslabšanja bolezni živeli dlje (12 mesecev) od tistih, ki so jemali drugo odobreno zdravilo, sorafenib (9 mesecev).
Fotivda can only be obtained with a prescription, and treatment should be supervised by a doctor with experience of treating cancers. 
Predpisovanje in izdaja zdravila Fotivda je le na recept, zdravljenje pa mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem raka.
By blocking this protein, tivozanib stops the formation of new blood vessels that the tumour needs, thereby cutting off its blood supply and reducing the growth of the cancer. 
Z zaviranjem te beljakovine tivozanib zaustavi nastanek novih krvnih žil, ki jih potrebuje tumor, s tem pa prekine dovod krvi do tumorja in zmanjša rast raka.
For more information about treatment with Fotivda, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Fotivda preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Fotivda may be used in previously untreated patients or in those whose disease has got worse despite treatment with another medicine working in a different way. 
Zdravilo Fotivda se lahko uporablja pri bolnikih, ki še niso bili zdravljeni, ali pri bolnikih, pri katerih se je bolezen kljub zdravljenju z drugim, drugače delujočim zdravilom, poslabšala.
The European Medicines Agency therefore concluded that the benefits of Fotivda outweighed its risk and recommended that it be granted authorisation in the EU. 
Evropska agencija za zdravila je zato zaključila, da koristi zdravila Fotivda odtehtajo z njim povezano tveganje, in priporočila, da se zanj izda dovoljenje za promet.
Fotivda is a medicine for treating adults with advanced renal cell carcinoma (a kidney cancer). 
Zdravilo Fotivda se uporablja za zdravljenje odraslih z napredovalim karcinomom ledvičnih celic (rakom ledvic).
On the whole, its side effects are in line with what is expected of a medicine of its class (VEGF inhibitors). 
V splošnem so neželeni učinki zdravila v skladu s pričakovanimi za zdravilo tega razreda (zaviralce VEGF).
It contains the active substance tivozanib. 
Vsebuje zdravilno učinkovino tivozanib.
The active substance in Fotivda, tivozanib, works by blocking the activity of proteins known as VEGF, which stimulate the formation of new blood vessels. 
Zdravilna učinkovina v zdravilu Fotivda, tivozanib, deluje tako, da zavira delovanje beljakovin, imenovanih VEGF, ki spodbujajo nastanek novih krvnih žil.
For practical information about using Fotivda, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Fotivda naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
How is Fotivda used? 
Kako se zdravilo Fotivda uporablja?
A main study showed that Fotivda increased the time it took for the disease to get worse by almost 3 months when compared with another approved medicine sorafenib. 
V glavni študiji so dokazali, da zdravilo Fotivda v primerjavi z drugim odobrenim zdravilom, sorafenibom, podaljša čas do poslabšanja bolezni za skoraj 3 mesece.
Patients must not take St John's wort (a herbal remedy for depression) during treatment with Fotivda. 
Bolniki med zdravljenjem z zdravilom Fotivda ne smejo jemati šentjanževke (zdravila rastlinskega izvora za zdravljenje depresije).
How does Fotivda work? 
Kako zdravilo Fotivda deluje?
More information on Uptravi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Več informacij o zdravilu Uptravi je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This also applies to any changes in the dose. 
To se nanaša tudi na vsako spremembo odmerka.
This could lead to patients receiving either too much (overdose) or too little (underdose) of the medicine. 
To lahko privede do tega, da bolniki prejemajo preveč (prevelik odmerek) ali premalo (premajhen odmerek) zdravila.
• If you have any questions regarding your treatment, please contact your doctor, pharmacist or nurse. 
• Če imate o svojem zdravljenju dodatna vprašanja, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
The fact that Uptravi is available in different strengths and that the dose is changed usually weekly during the titration phase may lead to confusion and errors by patients when taking the medicine. 
Dejstvo, da je zdravilo Uptravi na voljo v različnih jakostih in da se odmerek v fazi titriranja običajno tedensko spreminja, lahko pri bolnikih povzroči zmedenost in napake pri jemanju zdravila.
Measures to prevent medication errors due to weekly dose increases during initial titration phase 
Ukrepi za preprečevanje napak pri uporabi zdravila zaradi tedenskega povečevanja odmerka med začetno fazo titriranja
Treatment with Uptravi includes an initial titration phase, whereby the patient receives a low starting dose which is gradually increased over several weeks to a maintenance dose, which is continued longterm. 
Zdravljenje z zdravilom Uptravi obsega začetno fazo titriranja, v kateri bolnik prejme nizek začetni odmerek, ki se več tednov postopno povečuje do vzdrževalnega odmerka, ki ga prejema dolgotrajno.
Uptravi is a medicine used to treat adults with pulmonary arterial hypertension (PAH, abnormally high blood pressure in the arteries of the lungs). 
Zdravilo Uptravi se uporablja za zdravljenje odraslih s pljučno arterijsko hipertenzijo (PAH, nenormalno visok krvni tlak v pljučnih arterijah).
Healthcare professionals expected to prescribe and dispense Uptravi (selexipag) will be given an educational brochure to ensure that the medicine is used correctly. 
Zdravstveni delavci, za katere se pričakuje, da bodo predpisovali ali izdajali zdravilo Uptravi (seleksipag), bodo prejeli izobraževalno brošuro za zagotovitev pravilne uporabe zdravila.
• The first dose of Uptravi should always be taken in the evening. 
• Prvi odmerek zdravila Uptravi je treba vedno vzeti zvečer.
When the dose is changed, the new dose should also be first taken in the evening. 
Ob spremembi odmerka morate tudi novi odmerek najprej vzeti zvečer.
Patients will be given a diary to help them remember which dose to take. 
Bolniki bodo prejeli dnevnik, s pomočjo katerega se bodo lažje spomnili, kateri odmerek morajo vzeti.
• Before prescribing or dispensing Uptravi, healthcare professionals should give patients a titration guide and diary to help them keep track of the number of tablets they take. 
• Pred predpisovanjem ali izdajo zdravila Uptravi morajo zdravstveni delavci bolnikom dati navodilo in dnevnik za titriranje, ki jim bosta v pomoč pri sledenju števila tablet, ki jih bodo vzeli.
Once you have gone through the 4 steps of increasing the dose and are at step 5, you will be taking both the 200 microgram and the 800 microgram strengths at the same time. 
Ko boste opravili štiri korake povečevanja odmerka in boste pri petem koraku, boste jemali 200-mikrogramske in 800-mikrogramske tablete hkrati.
Underdosing may result in lack of effect whereas overdosing may lead to side effects such as headache, diarrhoea, nausea and vomiting. 
Premajhen odmerek lahko povzroči pomanjkanje učinka, prevelik pa neželene učinke, kot so glavobol, driska, slabost in bruhanje.
Uptravi is available in different strengths (200; 400; 600; 800; 1,000; 1,200; 1,400 and 1,600 micrograms). 
Zdravilo Uptravi je na voljo v različnih jakostih (200, 400, 600, 800, 1 000, 1 200, 1 400 in 1 600 mikrogramov).
• When prescribing Uptravi, healthcare professionals should follow the instructions provided in the summary of product characteristics and the educational material for Uptravi (brochure). 
• Pri predpisovanju zdravila Uptravi morajo zdravstveni delavci upoštevati navodila v povzetku glavnih značilnosti zdravila in izobraževalnemu gradivu za zdravilo Uptravi (brošura).
Use these boxes to write down the number of tablets you take. 
Te okvirčke uporabite za beleženje števila tablet, ki jih vzamete.
In addition, prescribers will only be able to prescribe Uptravi once they have registered with the company that markets Uptravi and received appropriate information on the safe and effective use of Uptravi. 
Poleg tega se bodo morali zdravniki, ki bodo zdravilo predpisovali, pred začetkom predpisovanja zdravila Uptravi registrirati pri družbi, ki ga trži, in prejeti ustrezne informacije o varni in učinkoviti uporabi tega zdravila.
PAH is a debilitating disease where there is severe narrowing of the blood vessels of the lungs. 
PAH je izčrpavajoča bolezen, pri kateri pride do hudega zoženja krvnih žil v pljučih.
The diary contains for each day and each strength two boxes for the patient to mark the number of tablets they take in the morning and evening. 
Dnevnik vsebuje za vsak dan in vsako jakost zdravila dva okvirčka, v katerih bolniki označijo število tablet, ki jih vzamejo zjutraj in zvečer.
• If during titration it is difficult to tolerate certain side effects, your doctor may reduce the dose by reducing the number of tablets that you take. 
• Če boste med povečevanjem odmerka težko prenašali nekatere neželene učinke, bo zdravnik odmerek morda zmanjšal z zmanjšanjem števila tablet, ki jih jemljete.
In case you are only using the 200 microgram strength, the diary pages look as follows: 
Če jemljete le tablete jakosti 200 mikrogramov, bodo strani v dnevniku videti takole:
• Uptravi is available as tablets in different strengths (200; 400; 600; 800; 1,000; 1,200; 1,400 and 1,600 micrograms). 
• Zdravilo Uptravi je na voljo v obliki tablet z različnimi jakostmi (200, 400, 600, 800, 1 000, 1 200, 1 400 in 1 600 mikrogramov).
Once a maintenance dose has been established, a different strength may be prescribed so that the patient takes only a single tablet twice daily. 
Ko je dosežen vzdrževalni odmerek, se lahko predpiše druga jakost, tako da bolnik jemlje le eno tableto dvakrat dnevno.
• Before prescribing Uptravi, healthcare professionals must register with the company's controlled access system. 
• Zdravstveni delavci se morajo pred predpisovanjem zdravila Uptravi registrirati v sistemu nadzorovanega dostopa družbe.
• You will be given a diary to help you keep track of the number of tablets you need to take during the titration phase. 
• Prejeli boste dnevnik, ki vam bo pomagal pri sledenju števila tablet, ki jih morate vzeti med povečevanjem odmerka.
• You will start treatment with one 200 microgram tablet twice a day, in the morning and in the evening (approximately 12 hours apart). 
• Zdravljenje boste začeli z eno 200-mikrogramsko tableto dvakrat dnevno, zjutraj in zvečer (približno 12 ur narazen).
The diary contains for each strength two boxes for each day of treatment, one for the morning dose and one for the evening dose. 
V dnevniku sta za posamezno jakost dva okvirčka za vsak dan zdravljenja, eden za jutranji in drugi za večerni odmerek.
• Once a suitable dose for you has been established (known as the maintenance dose), the doctor may prescribe a different strength of Uptravi tablet so you only need to take one tablet in the morning and one in the evening to get the right amount of the medicine. 
• Ko boste dosegli primeren odmerek (t. i. vzdrževalni odmerek), vam bo zdravnik morda predpisal tableto zdravila Uptravi druge jakosti, tako da boste za vnos ustrezne količine zdravila morali vzeti le eno tableto zjutraj in eno zvečer.
It is available as tablets to be taken by mouth. 
Na voljo je v obliki tablet, ki se jemljejo peroralno.
If side effects are manageable after stepping down the dose, your doctor may decide that you should stay on that dose. 
Če bodo neželeni učinki po zmanjšanju odmerka obvladljivi, se bo zdravnik morda odločil, da morate ostati pri tem odmerku.
During titration, the 200 and 800 micrograms strengths are used. 
Med titriranjem se uporabljata jakosti 200 in 800 mikrogramov.
During the titration phase only the 200 and 800 microgram strengths are used. 
V fazi povečevanja odmerka se uporabljata le jakosti 200 in 800 mikrogramov.
Treatment should be started at a dose of 200 micrograms twice a day, in the morning and in the evening. 
Zdravljenje je treba začeti z odmerkom 200 mikrogramov dvakrat dnevno, zjutraj in zvečer.
The 200 strength is used to step the dose up and down slowly during titration. 
Jakost 200 mikrogramov se uporablja za počasno stopenjsko povečevanje in zmanjševanje odmerka med titriranjem.
If the patient does not tolerate the dose, the doctor may decrease the dose. 
Če bolnik tega odmerka ne prenaša dobro, ga lahko zdravnik zmanjša.
• If you tolerate this dose, your doctor will then increase your dose usually every week by 200 micrograms twice daily, up to a maximum of 1,600 micrograms twice daily as detailed in the following diagram: 
• Če boste ta odmerek dobro prenašali, vam bo zdravnik odmerek povečeval običajno vsak teden za 200 mikrogramov dvakrat dnevno, do največ 1 600 mikrogramov dvakrat dnevno, kot je razvidno iz naslednjega diagrama:
Once a maintenance dose is established, the other strengths can be used to allow patients to take only one tablet in the morning and one in the evening, instead of multiple tablets each time. 
Ko je dosežen vzdrževalni odmerek, se lahko uporabijo druge jakosti, saj tako bolniki namesto več tablet hkrati jemljejo le eno tableto zjutraj in eno zvečer.
If you do not tolerate the dose, the doctor may decrease the dose to the previous step. 
Če določenega odmerka ne prenašate dobro, bo zdravnik morda zmanjšal njegovo jakost na tisto v predhodnem koraku.
If patients do not tolerate the dose, the dose may be decreased to the previous step. 
Če bolniki odmerka ne prenašajo dobro, je morda treba njegovo jakost zmanjšati na tisto v predhodnem koraku.
• If the patient tolerates the dose, the dose can be increased weekly by 200 micrograms twice daily, up to a maximum of 1,600 micrograms twice daily. 
• Če bolnik odmerek dobro prenaša, se lahko odmerek tedensko povečuje za 200 mikrogramov dvakrat dnevno, do največ 1 600 mikrogramov dvakrat dnevno.
If the patient tolerates the dose, the doctor may increase the dose every week by 200 micrograms twice daily, up to a maximum of 1,600 micrograms twice daily. 
Če bolnik ta odmerek dobro prenaša, lahko zdravnik odmerek tedensko povečuje za 200 mikrogramov dvakrat dnevno, do največ 1 600 mikrogramov dvakrat dnevno.
In this case you should refer to the following diary page to help you keep track of the number of tablets you need to take: 
V tem primeru pri sledenju števila tablet, ki jih morate vzeti, upoštevajte naslednjo stran v dnevniku: